Drug Safety in the Post-Vioxx Era: New legislation, regulation and company strategies in Europe and the US

Abstract

The new management report, Drug Safety in the Post-Vioxx Era: New legislation, regulation and company strategies in Europe and the US, examines the actions taken by legislative and regulatory bodies in response to recent drug safety concerns surrounding the COX-2 inhibitors and antidepressants. The report also analyzes the different management, marketing and technological strategies companies are pursuing to ensure the safety of their products, and provides predictions for the future of drug safety regulation in the US and EU.